更新于：2024-09-21
Flupenthixol Hydrochloride/Melitracen Hydrochloride
氟哌噻吨美利曲辛
更新于：2024-09-21
概要
基本信息
药物类型 小分子化药 |
别名 Flupentixol and Melitracen、盐酸氟哌噻吨/盐酸美利曲辛、Deanxit + [1] |
作用机制 DRDs拮抗剂(多巴胺受体家族拮抗剂)、单胺再摄取抑制剂 |
治疗领域 |
非在研适应症 |
原研机构 |
在研机构- |
最高研发阶段批准上市 |
首次获批日期- |
最高研发阶段(中国)批准上市 |
特殊审评- |
结构
分子式C52H67F3N4O2S |
InChIKeyMKWJDUAOJQMMSS-UHFFFAOYSA-N |
CAS号214556-54-4 |
关联
18
项与 氟哌噻吨美利曲辛 相关的临床试验氟哌噻吨美利曲辛片在健康受试者中的单剂量、空腹/餐后、随机、开放、两制剂、两周期、两交叉生物等效性研究
氟哌噻吨美利曲辛片在中国健康受试者中单中心、随机、开放、单次给药、两制剂、两周期交叉人体生物等效性研究
Efficacy of Deanxit with Tandospirone Citrate in Functional Dyspepsia Patient with anxiety and depression: A Randomized Controlled Trial
100 项与 氟哌噻吨美利曲辛 相关的临床结果
登录后查看更多信息
100 项与 氟哌噻吨美利曲辛 相关的转化医学
登录后查看更多信息
100 项与 氟哌噻吨美利曲辛 相关的专利（医药）
登录后查看更多信息
34
项与 氟哌噻吨美利曲辛 相关的文献（医药）2024-11-01Genes & Diseases
The efficacy and safety of NeuroWell antidepressant dietary supplement, Deanxit, and their combination in the treatment of mild-to-moderate depression: A randomized clinical trial
Article
作者: Wang, Wenwen ; Guo, Shang ; Wen, Xuejun ; Zhou, Qiqi ; Liu, Yue ; Li, Zhen ; Ning, Yaochao ; Zhang, Hui ; Liu, Dechen ; Wang, Qinglu ; Geng, Shuang ; Wang, Yutong ; Sui, Zhuxin ; Wang, Shanshan ; Sun, Lei ; Liu, Ping ; Yin, Honglei ; Wang, Hongwei ; Wang, Yunliang ; Wei, Dianfang ; Deng, Youping ; Liu, Yanqiu ; Liu, Yajun ; Zhang, Huaibo ; Wang, Yanchao ; Li, Jinfeng ; Zhang, Kezhong ; Yin, Hongtao
Then,a total of 242 participants were recruited,and 200 were eventually enrolled and randomly grouped (n Z 50)for the study.None of the patients in any of the four groups had dropped out by 12 wk.
2024-03-01Heliyon
Beyond the counter: Navigating the landscape of Deanxit® dispensing – Insights from Jordanian community pharmacies
Article
作者: Barakat, Muna ; Ahmad, Rawand E
Background:
This study investigates the dispensing patterns and knowledge of community pharmacists regarding Deanxit®, a combination of melitracen and flupentixol approved for the treatment of depression and anxiety in Jordan.
Methods:
This study employed a mixed-methods approach, involving 75 randomly selected pharmacies in two Jordanian governorates (Amman and Irbid). The investigation involved simulated patient scenarios and structured interviews employing a validated tool.
Results:
The analysis revealed that 70.6% of pharmacists were willing to dispense Deanxit® based on simulated scenarios, indicating malpractice. The mean practice score was 0.5867 out of 18, underlining a substantial level of malpractice. Pharmacists demonstrated poor knowledge, with a median score of 2.0 out of 15, reflecting a lack of awareness about Deanxit's labeled indications. Furthermore, 96% reported dispensing without prescriptions, and 62.1% acknowledged encountering cases of improper Deanxit® use.
Conclusion:
This study provides valuable insights into the current landscape of Deanxit® dispensing patterns, pharmacists' poor knowledge levels, and malpractices in Jordan. By identifying areas for improvement and offering recommendations for intervention, this study contributes to enhancing pharmacy practice and patient care outcomes in the region.
2023-05-01Heliyon
Melitracen and flupentixol (deanxit) use disorder in Lebanon
Article
作者: Kazzi, Ziad ; Al Hariri, Moustafa ; El Zahran, Tharwat ; Khalifeh, Malak ; Hammoud, Lina ; Al Hassan, Sally ; Aboukhater, Diana
Introduction:
Deanxit is a combination of melitracen and flupentixol, not approved as an antidepressant for sale and use in several countries but still widely available and commonly used among the Lebanese population. The study aimed to assess Deanxit use disorder, assess the source of the medication, and the consumers' awareness of the therapeutic and side effects of Deanxit, among the Lebanese population.
Methods:
This is a cross-sectional study that included all patients taking Deanxit and visited the Emergency Department between October 2019 and October 2020. All patients who agreed to participate in the research through written consent forms were contacted by telephone and a questionnaire was filled out.
Results:
A total of 125 patients taking Deanxit were included in the study. According to the DSM-V criteria, 36% (n = 45) had a Deanxit use disorder. Most of the participants were females (n = 99, 79.2%), married (n = 90, 72%), and between the ages of 40-65 years (n = 71, 56.8%). Most patients (n = 41, 91%) had Deanxit prescribed by a physician for anxiety (n = 28, 62%), and obtained it using a prescription (n = 41, 91%). Almost half of all patients (n = 60, 48%) did not have sufficient knowledge of the reason it was prescribed, 54.4% (n = 68) were not sure they are taking the medication appropriately, and 19.2% (n = 23) were satisfied by the overall explanation of the physicians concerning Deanxit use.
Conclusion:
Deanxit use disorder is underrecognized among Lebanese patients. Most of our patients were prescribed Deanxit by their physicians but reported inadequate knowledge of its side effects and risk of abuse.
100 项与 氟哌噻吨美利曲辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 焦虑症 | 中国 | - | - |
| 抑郁症 | 中国 | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿片相关性障碍 | 临床3期 | 中国 | 2014-10-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 160 | Control group | 壓糧鏇淵膚襯鹽醖鏇積(壓窪衊鑰夢壓鑰鹽繭糧) = 醖顧襯選簾糧鏇鹹遞醖 齋範憲繭窪製夢醖鑰憲 (願鬱選鹹構憲簾願積鑰 ) | - | 2019-06-15 | ||
壓糧鏇淵膚襯鹽醖鏇積(壓窪衊鑰夢壓鑰鹽繭糧) = 簾鹽鏇蓋網範繭餘構蓋 齋範憲繭窪製夢醖鑰憲 (願鬱選鹹構憲簾願積鑰 ) | |||||||
临床4期 | 262 | 糧膚膚餘壓鹽繭製築網(齋鹽艱願糧繭願鏇獵範) = 觸鑰繭簾糧觸範構夢選 衊網鬱鹽製遞糧蓋窪壓 (壓鹹繭繭繭壓壓簾簾築, 糧網願鹹鑰鏇壓築觸廠 ~ 顧獵簾願製觸窪糧構鑰) 更多 | - | 2015-02-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用